News from menarini ricerche A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

09 Jul, 2020, 08:00 BST Menarini Ricerche Announces the Latest Findings of Its Vaborem™ and Quofenix™ Clinical Studies

Menarini Ricerche, the R&D division of the Menarini Group, announces that it has published four abstracts presenting the latest findings related to...


02 Jul, 2020, 08:00 BST Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib/II Trial of MEN1611 in Colorectal Cancer

Menarini Ricerche, the R&D division of the Menarini Group, announced today that it plans to launch in the second-half of 2020 a new phase Ib/II trial ...


14 May, 2020, 14:05 BST 25th EHA Congress: Menarini Ricerche Discloses First Results From the Clinical Study on SEL24/MEN1703

Menarini Ricerche announces the completion of the dose escalation part of the First in Human, phase I/II DIAMOND trial (CLI24-001; NCT03008187)...


09 Dec, 2019, 08:00 GMT 61st ASH Congress 2019: Menarini Ricerche Presents the Latest Updates About the First In Human Clinical Trial of SEL24/MEN1703

Menarini Ricerche is progressing with the clinical development of SEL24/MEN1703, and will be presenting the design of the ongoing First In Human...


23 Sep, 2019, 08:00 BST ESMO Annual Meeting 2019: Menarini Ricerche Presents the Preclinical Characterization of MEN1611, a Novel PI3K Inhibitor in Development for the Treatment of Breast Cancer

Promising results from the preclinical study conducted by Menarini Ricerche on MEN1611, a potent and selective orally available phosphatidylinositol...


28 Jun, 2019, 08:00 BST Menarini Ricerche Announces Publication of Pre-clinical Data of the First-in-class Antibody-drug Conjugate MEN1309/OBT076, Currently in Phase I Clinical Development

Menarini Ricerche today announced the publication of the results of a non-clinical study describing the characterization of the anti-CD205...


10 Jun, 2019, 08:00 BST Menarini Ricerche at the 24ᵗʰ EHA Congress Presenting the First In Human Clinical Study of SEL24/MEN1703

Menarini Ricerche will present at the 24th EHA Congress 2019 in Amsterdam on the First In Human clinical trial of SEL24/MEN1703 (DIAMOND-01,...


23 May, 2019, 08:00 BST Menarini Ricerche at the ASCO Annual Meeting 2019 With Three Different Projects in Oncology

Menarini Ricerche will present three different projects related to the compounds in clinical development SEL24/MEN1703, MEN1611 and MEN1309/OBT076 at ...


19 Oct, 2018, 08:00 BST Menarini Progresses Into the Clinic With MEN1611, a PI3K Inhibitor for the Treatment of HER2 Positive Metastatic Breast Cancer

Menarini Ricerche announced today the initiation of the B-PRECISE-01 clinical trial, a multicenter phase Ib study that will evaluate the safety and...


19 Sep, 2018, 08:00 BST Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting

Menarini Ricerche will present tomorrow, September 20th, at the 60th Annual Meeting of the Italian Cancer Society (SIC), new preclinical data showing ...


06 Aug, 2018, 08:00 BST Menarini Ricerche to Sponsor Cancer Trial in Acute Myeloid Leukemia in USA

Menarini Ricerche, a company of the Menarini Group, announced today that the sponsorship of the ongoing Phase I/II study that is investigating...


01 Jun, 2018, 10:32 BST Menarini Ricerche to Present the Study Design of CD205-Shuttle, a First-in-human Trial of MEN1309/OBT076, at the ASCO Annual Meeting 2018

Menarini Ricerche (Menarini Group) will present at ASCO Annual Meeting 2018 the study design of CD205-Shuttle, a multicenter first-in-human clinical...


13 Apr, 2018, 08:00 BST Menarini Ricerche to Present the Most Recent Pre-clinical Data About the PI3K Inhibitor MEN1611 at the AACR Annual Meeting 2018

Menarini Ricerche will present on the latest preclinical studies of its phosphatidylinositol 3-kinase (PI3K) class I inhibitor MEN1611, in...